Education
About Us
Working with TipRanks
Follow Us
BioLife Solutions (BLFS)
NASDAQ:BLFS
Earnings Data
Report Date
May 08, 2025TBA Not Confirmed
Period Ending
2025 (Q1)Consensus EPS Forecast
-0.05Last Year’s EPS
-0.22Same Quarter Last Year
Strong Buy
Based on 8 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Mar 03, 2025
|% Change Since: -4.83%
|Next Earnings Date:May 08, 2025
Earnings Call Sentiment|Positive
The earnings call for BioLife Solutions reflected a positive outlook with significant achievements in strategic portfolio reshaping, improved financial metrics, and a strong cash position. Despite some declines in specific platform revenues and ongoing operating losses, the company is well-positioned for growth in 2025 with record Cell Processing revenue and a strong growth outlook.Company Guidance
During the BioLife Solutions' Q4 2024 conference call, the company provided revenue guidance for 2025, projecting total revenues between $95.5 million and $99 million, representing a growth of 16% to 20% compared to 2024. The Cell Processing platform is expected to contribute significantly to this growth, with anticipated revenue of $86.5 million to $89 million, reflecting an 18% to 21% increase. The Evo and Thaw platform is expected to generate $9 million to $10 million, marking a 3% to 15% growth. The company also aims for adjusted gross margins in the mid-60s and anticipates expanding adjusted EBITDA margins in 2025. The positive outlook is driven by continued growth from their Cell Processing platform, focusing on deepening relationships with existing customers and exploring cross-sell opportunities to enhance revenue.Strategic Portfolio Reshaping
BioLife Solutions strategically reshaped its portfolio in 2024, focusing on cell and gene therapies, divesting non-core product lines, and improving financial profiles.
Improved Financial Metrics
GAAP gross margin doubled from 31% in 2023 to 62% in 2024. Adjusted EBITDA was positive $16 million (19% of revenue), compared with negative $5 million in 2023.
Strong Cash Position
The company ended 2024 with $109 million in cash, up from $45 million in 2023, while paying down $5 million of principal on its bank debt.
Record Cell Processing Revenue
Cell Processing platform revenue was $20.3 million in Q4, up 7% over Q3 and a year-over-year increase of 37%. Full-year Cell Processing revenue totaled $74 million, increasing 12% compared to 2023.
2025 Growth Outlook
BioLife Solutions anticipates 2025 revenue growth of 16% to 20%, with Cell Processing revenue expected to grow between 18% to 21%.
---
BLFS Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
BLFS Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Mar 03, 2025 | $24.00 | $24.51 | +2.13% |
| Nov 12, 2024 | $26.50 | $24.11 | -9.02% |
| Aug 08, 2024 | $22.74 | $25.25 | +11.04% |
| May 09, 2024 | $18.01 | $19.54 | +8.50% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does BioLife Solutions (BLFS) report earnings?
BioLife Solutions (BLFS) is schdueled to report earning on May 08, 2025, TBA Not Confirmed.
What is BioLife Solutions (BLFS) earnings time?
BioLife Solutions (BLFS) earnings time is at May 08, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is BLFS EPS forecast?
BLFS EPS forecast for the fiscal quarter 2025 (Q1) is -0.05.
---